Kornimate/medical-research-clean huggingface dataset:
study of the transmission of cytomegalovirus (cmv) infection from mother to foetus

Conditions: Infections, Cytomegalovirus; Cytomegalovirus Infections

Summary: this study is designed to evaluate maternal virological and immunological parameters to determine their ability to predict congenital cytomegalovirus (cmv) infection. when a pregnant woman is infected with cmv, her immune system (which protects her from infection) is activated and the virus can be found in the woman's bodily fluids (blood, saliva, urine, vaginal secretions). the aim of this study is to find out if there is a link between either the pregnant woman's immune response or the presence of the virus in these bodily fluids and the child/foetus being infected with the virus.


Eligibility criteria:
inclusion criteria: * subjects who the investigator believes that they can and will comply with the requirements of the protocol . * a pregnant female, 18 years of age or older at the time of study enrolment. * women with confirmed primary cmv infection. * written informed consent obtained from the subject. exclusion criteria: * chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to study entry. * concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational pharmaceutical product. * previous vaccination against cmv infection. * any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history or physical examination * major congenital defects, serious chronic illness or organ transplantation. * administration of immunoglobulins and/or any blood products within the three months preceding study enrolment or during the pregnancy. * documented human immunodeficiency virus (hiv)-positive subject. * gestational age of more than 34 weeks, as determined by foetal ultrasound.

Keywords: pregnancy congenital cytomegalovirus infection
investigation of receptivity markers for endometrial cancer treatment development

Conditions: Endometrial Cancer Stage

Summary: hyaluronan is an extracellular matrix protein that is involved in cell-cell and cell-matrix interactions. hyaluronan performs this activity through hyaladherins, which are intracellular and extracellular receptors. the purpose of this study was to compare the distributions of hyaluronan synthetase 2 (has2) and cd44s in healthy endometrial tissue samples obtained during the proliferative phase endometrium (ppe) and secretory phase endometrium (spe), as well as pathologic samples diagnosed with benign endometrial hyperplasia (eh), endometrial intraepithelial neoplasia (ein), early stage of endometrial carcinoma (ec) (stage i/ii) and advanced stage of endometrial carcinoma (stage iii/iv) (n:5, each). by using the avidin-biotin-peroxidase method, tissue samples that had been fixed with formalin passed through a regular paraffin follow-up protocol, and subsequently embedded in paraffin were stained indirectly with anti-cd44s and anti-has2 primary antibodies. immunostaining intensity was graded as 0: negative, 1: weak, 2: moderate, 3: strong, and 4: very strong using a semiquantitative technique. the anova test was used to assess the statistical significance of the findings. statistical significance was defined as (p) values less than 0.05. while weak has2 and weak/moderate cd44s immunoreactivity was observed on the surface epithelium (se)/glandular epithelium (ge) and stroma of the tissue samples acquired during ppe; weak/moderate has2 and moderate cd44s immunoreactivity were observed in spe and eh groups; moderate/strong has2, strong cd44s immunoreactivity was observed in ein; strong/very strong has2 and very strong cd44s immunoreactivity were observed in early-stage ec and advanced stage ec. it was determined that the immunoreactivity intensity increased at a statistically significant level in both early and advanced stage ec. the fact that has2 and cd44s, two intracellular receptors, have increased in endometrial carcinoma leads us to believe that they are likely to play a role in tumor development, invasion, migration, metastasis and that they may be useful in developing future treatment protocols targeting hyaluronan receptors.


Eligibility criteria:
inclusion criteria: - all patients with endometrial carcinoma underwent surgery. exclusion criteria: * no patient was subject to chemotherapy or radiotherapy prior to surgery.

Keywords: endometrial carcinoma immunohistochemistry cd44s has2
the impact of night float on anesthesiology resident sleep patterns

Conditions: Sleep Disorders, Circadian Rhythm

Summary: residency training requires hospital presence twenty-four hours a day. at times this necessitates working extended shifts, including night shifts, resulting in altered sleep patterns and sleep deprivation. since 2003, the accreditation council for graduate medical education (acgme) has enforced duty hour regulations limiting shift length, the amount of weekly hours worked, and other variables governing shift work. numerous studies have sought to determine the impact of duty hour regulations on the quality of patient care and resident education. in addition to affecting patient care, medical resident sleep deprivation also has the potential to affect residents' well-being and their ability to perform basic tasks. a study in surgical residents showed reduced efficiency and safety in performing simulated laparoscopy following a period of sleep deprivation that was worse with novices compared to experienced residents. recently, uva found that resident physicians have greater difficulty controlling speed and driving performance with increased reaction times and minor and major lapses in attention in the driving simulator following six consecutive night shifts. to comply with duty hour restrictions, residency programs have adopted various strategies including the creation of night float systems where residents are required to work multiple nights in a row. reduced shift length has been associated with decreased medical errors, motor vehicle collisions, and percutaneous injuries.surgical residents who transitioned to a night float system from 24-hour call every 3rd day reported reduced fatigue, more time for sleep and independent reading and increased family time, while nurses and patients reported improved communication and quality of patient care. in a pilot study of urology residents assigned to a 12-hour day shift (monday-friday), 12-hour night float (sunday-friday) or 24-hour home call, actigraphy was used to measure total sleep time, sleep latency and depth of sleep. night float did not impact total sleep time or quality of sleep. however, these studies did not establish the optimal shift duration

participants wear a portable eeg monitor and a fitbit activity monitor while attempting to sleep while on night call and at home for a baseline reading

Eligibility criteria:
inclusion criteria: * postgraduate year (pgy) 2, 3, and 4 anesthesia residents exclusion criteria: * history of pacemaker or other medical device * unable or unwilling to consent and comply with the protocol * history of sleep disorder
safety and efficacy study of ac-3933 in adults with mild to moderate alzheimer's disease

Conditions: Alzheimer's Disease

Summary: the purpose of this study is to investigate efficacy and safety of different doses of ac-3933 in patients with mild to moderate alzheimer's disease.


Eligibility criteria:
inclusion criteria: * mild to moderate alzheimer's disease * male or female 55 years or older * living with caregiver * read, understand and speak english exclusion criteria: * need to drive during the study * treatment with acetylcholinesterase inhibitors or nmda antagonist, such as aricept or namenda, within 2 weeks of check-up and during the study * frequent smoker * frequent consumer of caffeine

Keywords: alzheimer dementia
conversational hypnosis in women undergoing imaging for breast cancer

Conditions: Breast Cancer

Summary: the hypothesis is to assess the contribution of conversational hypnosis on anxiety of patients who undergoing for a preoperative breast tracking and improve their care


Eligibility criteria:
inclusion criteria: * adult patients ≥ 18 years old * eastern cooperative oncology group (ecog) performance status ≤ 2 * patient undergoing for a preoperative breast assessment * patient must be affiliated to a social security system * ability to provide an informed written consent form exclusion criteria: * patients diagnosed with major hearing loss * patients with schizophrenia * patients do not understand the french language * pregnant or breast feeding females * refusal of the patient to participate in the study * persons deprived of liberty or under supervision

Keywords: conversational hypnosis imaging care breast neoplasia anxiety pain
surveillance trial to evaluate a shortened infusion time of intravenous ibuprofen

Conditions: Pain; Fever

Summary: the primary objective of this study is to determine the safety of a single dose of intravenous ibuprofen administered over 5-10 minutes for the treatment of fever or pain in the hospital setting.


Eligibility criteria:
inclusion criteria: * pain: patients with baseline visual analog scale assessment \>3, -and/or- fever: patients with temperature \>101°f. exclusion criteria: 1. patients with inadequate iv access 2. patients \<18 years of age 3. history or allergy or hypersensitivity to any component of intravenous ibuprofen, aspirin (or aspirin related products) or non-steroidal anti-inflammatory drug (nsaids) 4. active hemorrhage or clinically significant bleeding 5. pregnant or nursing 6. patients in the peri-operative period in the setting of coronary artery bypass graft (cabg) surgery 7. inability to understand the requirements of the study, be willing to provide written informed consent (as evidenced by signature on an informed consent document approved by an institutional review board \[irb\]), and agree to abide by the study restrictions 8. refusal to provide written authorization for use and disclosure of protected health information

Keywords: pain fever
contribution of the pharmacological profile of the a2a receptor to adenosine in the diagnosis of myocardial ischemia

Conditions: Chronic Coronary Artery Disease

Summary: the chronic coronary artery disease could be detected by a drop in the expression of a2a receptors to adenosine, while high values of the kd / ec50 ratio are a sign of coronary ischemia. knowing the number of a2a receptors in circulating lymphocytes could allow detection of coronary artery disease and evaluating the functionality of a2a receptors in circulating lymphocytes could allow quantification of myocardial ischemia. thus, a simple and unique blood sample would quickly detect patients with life-threatening coronary ischemia. this would avoid prolonged hospitalizations and costly non-invasive tests (stress echocardiography, myocardial scintigraphy) in patients without coronary artery disease.

the main objective of this study is to evaluate the discriminating capacities of a2a adenosine receptors expression on the surface of circulating lymphocytes for the detection of coronary artery disease in patients hospitalized for surgery of the aorta and / or arteries of the lower limbs. the secondary objectives are: assessment of the discriminating capacities of the functionality (kd / ec50) of a2a adenosine receptors on the surface of circulating lymphocytes, for the diagnosis of myocardial ischemia in patients hospitalized for surgery of the aorta and / or arteries of legs. determinate the best threshold for discriminating patients with coronary artery disease and estimate the discriminating performance associated with this threshold. determinate the best threshold for discriminating patients with myocardial ischemia and estimate the discriminating performance associated with this threshold.

Eligibility criteria:
inclusion criteria: * patients admitted for preoperative assessment of vascular surgery of the aorta and / or arteries of the lower limbs. * adult person (age\> 18). * affiliated with a social security scheme. * signature of informed consent. exclusion criteria: * patients with a history of coronary artery disease awaiting revascularization. * hyperthyroidism, anemia (hb \<13 g / dl). * contraindication to the practice of coronary angiography, stress echocardiography or myocardial scintigraphy. * unstable hemodynamic state or cardiogenic shock. * adults protected under guardianship, curatorship or legal protection. * pregnant or lactating women
inflammation markers over time in cardiovascular disease

Conditions: Cardiovascular Diseases; Coronary Disease; Heart Diseases; Thrombosis; Inflammation

Summary: to determine inflammation markers over time in cardiovascular disease. to test the hypothesis that measures of coagulation and fibrinolysis correlate with the incidence of coronary heart disease (chd) and other thrombosis related disorders, and to help identify those individuals at greatest risk, using the cardiovascular health study (chs) and honolulu heart program (hhp) populations. these two genetically distinct populations had different event rates for chd, and offered a unique opportunity to test associations that were uncovered by comparing results across populations.

background: coronary heart disease (chd) and other thrombosis related disorders are a major source of morbidity and mortality in the united states and the world. to a certain extent they are diseases of the elderly, with the majority of overt chd occurring in persons over the age of 65. recently, fibrinogen and factor vii have been implicated as independent chd risk factors in middle age populations, although causative roles have not been established. these studies increased understanding of the relationship of thrombosis to cardiovascular risk. design narrative: beginning in 1992, the study tested the hypothesis that measures of coagulation and fibrinolysis correlated with the incidence of coronary heart disease (chd) and other thrombosis related disorders, and identified those individuals at greatest risk, using the cardiovascular health study (chs) and honolulu heart program (hhp) populations. these two genetically distinct populations had different event rates for chd, and offered a unique opportunity to test associations that were uncovered by comparing results across populations. the study examined selected measures of coagulation and fibrinolysis in individuals 65 years and older: measures of pro-coagulation (factor antigen vii, prothrombin fragment 1.2, fibrinopeptide a and thrombin - antithrombin iii complex), measures of coagulation inhibition (protein c and protein s, antithrombin iii, and the lipoprotein associated coagulation inhibitor (laci), and measures of fibrinolysis (plasminogen activator inhibitor-1 (pai-1), tissue plasminogen activator-pai-1 complex, plasmin-alpha-2 antiplasmin complex, and lp(a). a case/control design was used to determine the relationship between the above measurements and the incidence of chd (and other thrombosis related disorders). the short and medium term biological variability of the above measures was determined to aid in interpretation of observed differences. finally, the distribution of the above measurements was established in both cohorts and their relationships to other variables in the extensive chs and hhp data bases ascertained. the study was renewed in 1999 to determine inflammation markers over time in cardiovascular disease. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
a 28-day parallel group study of td-4208 in chronic obstructive pulmonary disease (copd)

Conditions: COPD

Summary: this study evaluated the safety and efficacy of four doses of td-4208 and a placebo product when administered once daily for 28 days using a jet nebulizer to patients with moderate to severe chronic obstructive pulmonary disease.


Eligibility criteria:
inclusion criteria: * subject is a male or female subject 40 years of age or older * subject must have a negative pregnancy test, and must be prepared to use effective contraception if of child-bearing potential * subject is capable of performing reproducible spirometry maneuvers * subject has post-bronchodilator fev1/fvc ratio \<0.7 * subject has moderate-to-severe stable copd (stage 2 or 3 according to the gold guidelines) * subject has a post-bronchodilator fev1 greater than or equal to 30% and less than 80% of predicted normal * subject has a current or past smoking history of at least 10 pack-years. exclusion criteria: * subject has a significant respiratory disease or disorder other than copd that would affect the interpretation of data from this study * subject has a history of reactions or hypersensitivity to inhaled or nebulized anticholinergic or beta-agonist agents * subject suffers from any medical condition that would preclude the use of inhaled anticholinergic agents * subject has been hospitalized for copd or pneumonia within 12 weeks * subject requires long-term oxygen therapy (\>15 hours a day)

Keywords: copd chronic obstructive pulmonary disease
safety of repeat doses of iv serelaxin in subjects with chronic heart failure

Conditions: Chronic Heart Failure

Summary: the purpose of this study was to assess the safety of repeat doses of serelaxin in chronic heart failure.


Eligibility criteria:
key inclusion criteria: * body weight of ≤ 160 kg. * subjects with compensated chf (nyha class ii - iii) at time of screening with a prior documented history of chronic heart failure. * nt-probnp \>300 pg/ml (according to central measurement) at visit 1. * subjects treated with appropriate and guideline-indicated chf standard of care. * ability to comply with all requirements, including ability to receive at least a 48 hour infusion plus follow-up time required for each dosing visit. key exclusion criteria: * current acute decompensated hf * any major solid organ transplant recipient or planned anticipated organ transplant within 1 year. * documented history of untreated ventricular arrhythmia with syncopal episodes, ventricular tachycardia, or ventricular fibrillation without icd (implantable cardioverter defibrillator) with significant hemodynamic consequences within the 3 months prior to screening. * presence of hemodynamically significant mitral and /or aortic valve disease, except mitral regurgitation secondary to left ventricular dilatation: including significant left ventricular outflow obstruction (e.g., obstructive hypertrophic cardiomyopathy, severe aortic stenosis) * subjects with severe renal impairment defined as pre-randomization egfr \< 30 ml/min/1.73m2 calculated using the smdrd equation and/or those receiving current or planned dialysis or ultrafiltration

Keywords: chronic heart failure, chf, heart failure, hf, immunogenicity, anti-bodies, hypersensitivity, serelaxin, relax-repeat
dosage schedule study of pemetrexed monochemotherapy for locally advanced or metastatic non-small cell lung cancer (nsclc)

Conditions: Non Small Cell Lung Cancer

Summary: patients affected by non-small cell lung cancer (nsclc) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles. pemetrexed is an enhancer of some biomolecules involved in the gemcitabine mechanism of action. purpose of the trial is to monitor the blood values of these biomolecules at different time intervals, to optimize the synergism between pemetrexed and gemcitabine.


Eligibility criteria:
inclusion criteria * histologically or cytologically proven iiib and iv nsclc. * no symptomatic uncontrolled brain metastasis * not suitable for platinum containing regimens if chemo-naive * performance status less than or equal to 2 on the eastern cooperative oncology group (ecog) scale. * creatinine clearance (crcl) greater than or equal to 45 milliliters per min (ml/min) exclusion criteria * prior radiation to greater than 25% of bone marrow * inability to interrupt aspirin at doses of greater than 1.3 grams/day or non-steroidal anti-inflammatory agents for a 5-day period. * presence of clinically relevant third-space fluid collections not controllable. * significant cardiac disease
effects of applying kinesio tapping on primary dysmenorrhea in football players

Conditions: Primary Dysmenorrhea (PD)

Summary: the objective of this clinical study is to investigate the effects of applying kinesio taping to female soccer players with pd and comparing this application with a placebo group.

women's football has grown in the last decade, but there is still a need to study how the menstrual cycle affects players' performance. primary dysmenorrhea (pd), a common menstrual pain, impacts between 50% and 90% of women, reducing their participation in sporting activities. many players notice that their performance is affected during the cycle, and the use of anti-inflammatories is not always effective. therefore, it is important to implement simple measures that improve the quality of life and performance of players. alternatives such as physical therapy and kinesio taping (kt) can help alleviate symptoms. the literature shows that kt is a technique with the potential to produce tactile sensory impulses on the skin, which can block or reduce the arrival of painful sensations to the brain, and could therefore be interesting in the treatment of pd. therefore, the present study aims to investigate the effects of applying kinesio taping to female soccer players with pd and comparing this application with a placebo group.

Eligibility criteria:
inclusion criteria: * women practicing football from the mulheres em campo project * primary dysmenorrhea * aged between 15 and 17 years * regular menstrual cycle (28 ± 7 days) * nulliparous * not having an intrauterine contraceptive device or using oral contraceptives * dp will be defined according to the visual analogue scale from 5 points. exclusion criteria: * women who do not play football in the mulheres em campo project * secondary dysmenorrhea * diagnosed with serious comorbidity * skin lesions in the abdominal region * allergy to adhesive tapes.

Keywords: primary dysmenorrhea kinesio taping female football